Aliases & Classifications for Liposarcoma

MalaCards integrated aliases for Liposarcoma:

Name: Liposarcoma 12 75 53 55 44 15 17 72

Classifications:



External Ids:

Disease Ontology 12 DOID:3382
MeSH 44 D008080
NCIt 50 C3194
SNOMED-CT 68 49430005
UMLS 72 C0023827

Summaries for Liposarcoma

NIH Rare Diseases : 53 Liposarcoma is a tumor that arises from fat tissue. This tumor often occurs in the thigh, legs, behind the knee, or in the abdomen, but it can be found in other parts of the body, in the retroperitoneum; and, less often, in the head and neck area. Their primary occurrence in the skin is rare. Because a liposarcoma may grow into surrounding tissues or organs, it is considered a malignant tumor. The World Health Organization classification of soft tissue tumors recognizes 5 types of liposarcomas: Well differentiated, which includes the adipocytic, sclerosing, and inflammatory subtypes; dedifferentiated; myxoid; round cell; and pleomorphic. Most patients with liposarcoma have no symptoms until the tumor is large and invades the neighboring organs or tissues, causing tenderness, pain, or functional problems. Although surgical removal of the tumor is the curative treatment, some patients may benefit from chemotherapy and radiation. Most patients with liposarcoma have no symptoms until the tumor is large and impinges on neighboring structures, causing tenderness, pain, or functional disturbances. In the retroperitoneal area, where liposarcoma is detected at a late stage, the tumor may grow to a substantial size, weighing several pounds at the time of diagnosis. In general, liposarcoma grows silently, and the patient's estimation of the clinical duration is often unreliable. The patient eventually becomes aware of a swelling or a mass and reports this finding to the physician. Patients may report the following: Associated episode of trauma to the region containing the mass Painful swelling (occurs in one third of cases for as long as 6 mo) Decreased function (ie, range of motion) Numbness Enlargement of varicose veins Fatigue Abdominal pain Weight loss Nausea Vomiting

MalaCards based summary : Liposarcoma is related to cellular myxoid liposarcoma and pleomorphic liposarcoma. An important gene associated with Liposarcoma is FUS (FUS RNA Binding Protein), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Cyclophosphamide and Mechlorethamine have been mentioned in the context of this disorder. Affiliated tissues include bone, breast and adipocyte, and related phenotypes are subcutaneous nodule and sarcoma

Disease Ontology : 12 A lipomatous cancer that arises in fat cells in deep soft tissue retroperitoneum and the extremities.

Wikipedia : 75 Liposarcoma is a cancer that arises in fat cells in soft tissue, such as that inside the thigh or in the... more...

Related Diseases for Liposarcoma

Diseases in the Liposarcoma family:

Adult Liposarcoma Inflammatory Liposarcoma

Diseases related to Liposarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 549)
# Related Disease Score Top Affiliating Genes
1 cellular myxoid liposarcoma 34.3 MDM2 FUS EWSR1 CDK4
2 pleomorphic liposarcoma 34.0 VIM MDM2 DES CDKN2A
3 well-differentiated liposarcoma 33.9 TSPAN31 MDM2 HMGA2 CDKN2A CDK4
4 dedifferentiated liposarcoma 33.9 TP53 MDM2 HMGA2 DES CDKN2A CDK4
5 myxoid liposarcoma 33.6 TP53 MDM2 LRP1 HMGA2 FUS EWSR1
6 sclerosing liposarcoma 33.1 TP53 MDM2 MB FUS CD34
7 mixed liposarcoma 33.0 MDM2 MB FUS DDIT3 CDK4 CD34
8 spindle cell liposarcoma 32.9 MDM2 DDIT3 CDK4 CD34 CALB2
9 pleomorphic lipoma 32.5 MDM2 HMGA2
10 soft tissue sarcoma 32.1 TP53 MDM2 EWSR1
11 lipomatosis, multiple 31.8 MDM2 HMGA2 FUS DES CDK4
12 myxofibrosarcoma 31.6 MDM2 FUS DES
13 spindle cell sarcoma 31.4 VIM MDM2 DES
14 malignant fibroxanthoma 31.4 VIM MDM2 DES CDK4
15 fibrous histiocytoma 31.4 VIM FUS EWSR1 DES
16 angiolipoma 31.2 VIM DES
17 spindle cell lipoma 31.0 VIM MDM2 DES CDK4
18 li-fraumeni syndrome 30.9 TP53 MDM2 CDKN2A
19 sarcomatosis 30.9 HMGA2 EWSR1
20 mesenchymoma 30.9 MDM2 MB HMGA2 DES
21 hemangiopericytoma, malignant 30.8 VIM MDM2 DES
22 inflammatory mfh 30.8 MDM2 CDK4
23 chondroid lipoma 30.8 MDM2 FUS DDIT3 CDK4
24 retinoblastoma 30.8 TP53 MDM2 CDKN2A CDK4
25 chondrosarcoma, extraskeletal myxoid 30.7 FUS EWSR1 DDIT3
26 retroperitoneal fibrosis 30.6 VIM MDM2
27 carcinosarcoma 30.6 VIM TP53 DES
28 embryonal sarcoma 30.5 VIM TP53 MDM2 DES CDK4
29 histiocytoma 30.5 TSPAN31 TP53 MDM2 MB FUS EWSR1
30 leiomyosarcoma 30.5 VIM TP53 MDM2 MB DES CDK4
31 pleomorphic adenoma 30.4 VIM TP53 MDM2 HMGA2
32 infiltrating lipoma 30.4 MDM2 HMGA2 CDK4 CD34
33 sarcoma 30.4 VIM TP53 MDM2 FUS EWSR1 DDIT3
34 malignant peritoneal mesothelioma 30.4 VIM CDKN2A
35 inflammatory myofibroblastic tumor 30.4 VIM TP53 MDM2 DES CDK4
36 malignant peripheral nerve sheath tumor 30.4 VIM TP53 MDM2 CDKN2A CDK4
37 malignant mesenchymoma 30.3 TP53 MDM2 MB EWSR1 DES CDK4
38 chordoma 30.3 VIM DES CDKN2A
39 glomus tumor 30.2 VIM TP53 DES
40 uterine sarcoma 30.2 MDM2 MB DES
41 leiomyoma 30.1 VIM HMGA2 DES CD34
42 embryonal rhabdomyosarcoma 30.1 MB EWSR1 DES
43 glioblastoma multiforme 30.0 TP53 PPARG MDM2 CDKN2A CDK4
44 glioblastoma 30.0 TP53 PPARG MDM2 CDKN2A CDK4
45 gallbladder sarcoma 29.9 DES CD34
46 cavernous hemangioma 29.9 VIM MB DES
47 rhabdomyosarcoma 29.9 VIM TP53 MDM2 MB EWSR1 DES
48 sarcoma, synovial 29.8 VIM MDM2 HMGA2 DES CALB2
49 gastrointestinal stromal tumor 29.7 VIM TP53 DES CDKN2A CD34
50 dermatofibrosarcoma protuberans 29.7 VIM TP53 DES CD34

Graphical network of the top 20 diseases related to Liposarcoma:



Diseases related to Liposarcoma

Symptoms & Phenotypes for Liposarcoma

Human phenotypes related to Liposarcoma:

32 (show all 9)
# Description HPO Frequency HPO Source Accession
1 subcutaneous nodule 32 hallmark (90%) HP:0001482
2 sarcoma 32 hallmark (90%) HP:0100242
3 nausea and vomiting 32 occasional (7.5%) HP:0002017
4 fatigue 32 occasional (7.5%) HP:0012378
5 abdominal pain 32 occasional (7.5%) HP:0002027
6 weight loss 32 occasional (7.5%) HP:0001824
7 paresthesia 32 occasional (7.5%) HP:0003401
8 abnormality of the kidney 32 occasional (7.5%) HP:0000077
9 varicose veins 32 occasional (7.5%) HP:0002619

GenomeRNAi Phenotypes related to Liposarcoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 CD34 CDK4 DDIT3 DES MDM2 PPARG

MGI Mouse Phenotypes related to Liposarcoma:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.3 CD34 CDK4 CDKN2A DDIT3 DES LRP1
2 cardiovascular system MP:0005385 10.26 CDK4 CDKN2A DDIT3 DES LRP1 MB
3 behavior/neurological MP:0005386 10.24 CALB2 CDK4 CDKN2A DDIT3 DES LRP1
4 homeostasis/metabolism MP:0005376 10.21 CD34 CDK4 CDKN2A DDIT3 DES LRP1
5 hematopoietic system MP:0005397 10.18 CD34 CDK4 CDKN2A DDIT3 LRP1 MB
6 embryo MP:0005380 10.09 CDK4 CDKN2A LRP1 MB MDM2 PPARG
7 immune system MP:0005387 10.06 CD34 CDK4 CDKN2A DDIT3 LRP1 MDM2
8 integument MP:0010771 9.91 CD34 CDK4 CDKN2A LRP1 MDM2 PPARA
9 liver/biliary system MP:0005370 9.81 CDK4 CDKN2A DDIT3 LRP1 MDM2 PPARA
10 muscle MP:0005369 9.65 CDK4 CDKN2A DES LRP1 MB MDM2
11 neoplasm MP:0002006 9.17 CD34 CDK4 CDKN2A DDIT3 MDM2 PPARG

Drugs & Therapeutics for Liposarcoma

Drugs for Liposarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 146)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
2
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
3
Lenograstim Approved, Investigational Phase 3 135968-09-1
4
Daunorubicin Approved Phase 2, Phase 3 20830-81-3 30323
5
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
6
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
7
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
8
Gemcitabine Approved Phase 3 95058-81-4 60750
9
Dacarbazine Approved, Investigational Phase 3 4342-03-4 5351166
10
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
11
Etoposide Approved Phase 3 33419-42-0 36462
12
Epirubicin Approved Phase 3 56420-45-2 41867
13
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
14 Olaratumab Approved, Investigational Phase 3 1024603-93-7
15
Ifosfamide Approved Phase 3 3778-73-2 3690
16
Histamine Approved, Investigational Phase 3 51-45-6 774
17
Cyproheptadine Approved Phase 3 129-03-3 2913
18 Pharmaceutical Solutions Phase 3
19 Immunosuppressive Agents Phase 3
20 Antirheumatic Agents Phase 3
21 Nucleic Acid Synthesis Inhibitors Phase 3
22 Antimetabolites, Antineoplastic Phase 3
23 Antimetabolites Phase 3
24 Tubulin Modulators Phase 3
25 Antimitotic Agents Phase 3
26 Antineoplastic Agents, Phytogenic Phase 3
27 Etoposide phosphate Phase 3
28 Anti-Bacterial Agents Phase 3
29 Antibiotics, Antitubercular Phase 3
30
Liposomal doxorubicin Phase 3 31703
31 Topoisomerase Inhibitors Phase 3
32
Isophosphamide mustard Phase 3 0
33 Gastrointestinal Agents Phase 3
34 Neurotransmitter Agents Phase 3
35 Anti-Allergic Agents Phase 3
36 Serotonin Antagonists Phase 3
37 Histamine H1 Antagonists Phase 3
38 Histamine Antagonists Phase 3
39 Dermatologic Agents Phase 3
40 Serotonin Agents Phase 3
41
Histamine Phosphate Phase 3 51-74-1 65513
42 Antipruritics Phase 3
43
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
44
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
45
Rosiglitazone Approved, Investigational Phase 2 122320-73-4 77999
46
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
47
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
48
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
49
Mecasermin Approved, Investigational Phase 2 68562-41-4
50
Bevacizumab Approved, Investigational Phase 2 216974-75-3

Interventional clinical trials:

(show top 50) (show all 146)
# Name Status NCT ID Phase Drugs
1 A Phase III Randomized Study of Preoperative Radiotherapy Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcoma (RPS) Unknown status NCT01344018 Phase 3
2 Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
3 Phase III Study of The Role of Barrier Resection in Local Control in Treatment of Extremity Soft Tissue Sarcomas Unknown status NCT02120768 Phase 3
4 A Randomized Controlled Study of YONDELIS (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma Completed NCT01343277 Phase 3 Trabectedin;Dacarbazine
5 Multicenter, Open-label Study of YONDELIS (Trabectedin) in Subjects With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma Completed NCT01692678 Phase 3 Trabectedin;Dacarbazine
6 A Phase III Randomized Study of Preoperative Radiation Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcomas (RPS) Completed NCT00091351 Phase 3
7 Randomised Trial of Post-Operative Radiotherapy Given to Adult Patients With Extremity Soft Tissue Sarcoma [VORTEX] Completed NCT00423618 Phase 3
8 Randomised Trial Of Single Agent Doxorubicin Versus Doxorubicin Plus Ifosfamide In The First Line Treatment Of Advanced Or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
9 Randomized Phase III Trial of Two Investigational Schedules of Ifosfamide vs. Standard Dose Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
10 Randomized Study Comparing Neoadjuvant Chemotherapy Etoposide + Ifosfamide + Adriamycin (EIA) Combined With Regional Hyperthermia (RHT) Versus Neoadjuvant Chemotherapy Alone in the Treatment of High-Risk Soft Tissue Sarcomas in Adults Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
11 METASTASECTOMY AND CHEMOTHERAPY FOR LUNG METASTASES FROM SOFT TISSUE SARCOMA: A RANDOMIZED PHASE III STUDY (AN INTERGROUP STUDY WITH THE SCANDINAVIAN SARCOMA GROUP) Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
12 RANDOMISED TRIAL OF ADJUVANT CHEMOTHERAPY WITH HIGH-DOSE DOXORUBICIN, IFOSFAMIDE AND LENOGRASTIM IN HIGH GRADE SOFT TISSUE SARCOMA Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
13 Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754) Completed NCT02180867 Phase 2, Phase 3 Doxorubicin;Doxorubicin Hydrochloride;Ifosfamide;Pazopanib;Pazopanib Hydrochloride
14 Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
15 MMT 95 Study For Rhabdomyosarcoma and Other Malignant Soft Tissue Tumors of Childhood Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
16 A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS) Recruiting NCT02606461 Phase 2, Phase 3 Selinexor;Placebo
17 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3 epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3);gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8);trabectedin 1.3 mg/m2;high-dose ifosfamide 14 g/m2, given in in 14 days;etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3);gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
18 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin Plus Olaratumab Versus Doxorubicin Plus Placebo in Patients With Advanced or Metastatic Soft Tissue Sarcoma Active, not recruiting NCT02451943 Phase 3 Olaratumab;Doxorubicin;Placebo
19 A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients With High Risk RetroPeritoneal Sarcoma (RPS) Not yet recruiting NCT04031677 Phase 3 Preoperative chemotherapy
20 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
21 Time to Secondary Resistance to Trabectedin After Interruption Versus Continuation in Responding Patients With Liposarcoma, Leiomyosarcoma and Synovial Sarcoma Withdrawn NCT03773510 Phase 3 Trabectedin discontinuation;Trabectedin continuation
22 A Phase II, Multicenter Study to Explore the Efficacy and Safety of Brostallicin in Patients With Myxoid Liposarcoma With (12:16) Translocation Unknown status NCT00633165 Phase 2 Brostallicin
23 A Phase II Single Arm Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well-Differentiated or Dedifferentiated Liposarcoma Unknown status NCT02571829 Phase 2 ribociclib
24 GEIS-27: Phase I/II Multicenter and Prospective Trial of Nilotinib and Adriamycin as Neoadjuvant Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum Unknown status NCT02587169 Phase 1, Phase 2 Nilotinib-adriamycin
25 Phase I-II Prospective Trial, Multicenter, Open Label, Exploring the Combination of Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients Unknown status NCT02275286 Phase 1, Phase 2 Trabectedin
26 Non-randomized Single-center Study Phase II Evaluating the Efficacy and Toxicity of Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma Unknown status NCT01883518 Phase 1, Phase 2
27 Randomized Phase II Study of Brostallicin (PNU-166196A) Versus Doxorubicin as First Line Chemotherapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
28 Phase II Evaluation of Temodal (Temozolomide, Schering) in Previously Treated Advanced Sarcomas Unknown status NCT00003718 Phase 2 temozolomide
29 A Phase II Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma Completed NCT01506596 Phase 2 pazopanib
30 Phase II Clinical Trial of TROGLITAZONE, a Ligand for the Peroxisome Proliferator-Activated Receptor Gamma (PPAR), as Antineoplastic Differentiation Therapy for Patients With Malignant Liposarcoma Completed NCT00003058 Phase 2 troglitazone
31 A Multicenter Phase II Clinical Trial of Neoadjuvant Trabectedin (Yondelis) in Patients With Localized Myxoid / Round Cell Liposarcoma Completed NCT00579501 Phase 2 Trabectedin;Dexamethasone
32 Phase II Clinical Trial of Rosiglitazone, a Full-Agonist Ligand for the Peroxisome Proliferator-Activated Receptor Gamma (PPAR), as Differentiation Therapy for Patients With Liposarcoma Completed NCT00004180 Phase 2 rosiglitazone maleate
33 A Phase II Study on Trabectedin in Advanced Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma Completed NCT02247544 Phase 2 Trabectedin
34 A Phase II Study Of PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma Completed NCT01209598 Phase 2 Palbociclib 200mg;Palbociclib 125mg
35 Phase II Clinical Trial of Pazopanib to Evaluate the Activity and Tolerability in Patients With Advanced and/or Metastatic Liposarcoma Who Have Relapsed Following Standard Therapies or for Whom no Standard Therapy Exists Completed NCT01692496 Phase 2 Pazopanib
36 Phase II Open-Label Study of Sunitinib Malate (SU011248) in Adult Patients With Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Completed NCT00400569 Phase 2 Sunitinib Malate (SU011248)
37 A Phase II Study of AP23573, An mTOR Inhibitor, in Patients With Advanced Sarcoma Completed NCT00093080 Phase 2 ridaforolimus
38 A Randomized, Multicenter, Open-label Study of Yondelis (ET-743 Ecteinascidin) Administered by 2 Different Schedules (Weekly for 3 of 4 Weeks vs. q3 Weeks) in Subjects With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma Following Treatment With an Anthracycline and Ifosfamide Completed NCT00060944 Phase 2 Yondelis;Yondelis;Dexamethasone;Dexamethasone
39 A Randomized, Open-Label, Phase 2 Trial of CMB305 (Sequentially Administered LV305 and G305) and Atezolizumab in Patients With Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY-ESO-1 Completed NCT02609984 Phase 2
40 Phase II Trial of BAY-9006 (NSC #724772) in Advanced Soft Tissue Sarcomas Completed NCT00217620 Phase 2 sorafenib
41 Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
42 A Phase 2 Study of AZD0530 in Recurrent or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
43 A Phase II Study of Single Agent Depsipeptide (FK228) in Metastatic or Unresectable Soft Tissue Sarcomas Completed NCT00112463 Phase 2 romidepsin
44 Phase II Study on ET-743 in Advanced Soft Tissue Sarcomas of the Adult Completed NCT00003939 Phase 2 trabectedin
45 Exatecan As Second-Line Treatment In Advanced Adult Soft Tissue Sarcoma: A Phase II - Study Of The EORTC Soft Tissue And Bone Sarcoma Group Completed NCT00041236 Phase 2 exatecan mesylate
46 Phase I/II Trial of Torisel and Liposomal Doxorubicin in Patients With Advanced Soft Tissue and Bone Sarcomas Completed NCT00949325 Phase 1, Phase 2 temsirolimus plus liposomal doxorubicin
47 A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas. Completed NCT00642941 Phase 2 RG1507
48 A Phase II Randomized - Non Comparative - Study on the Activity of Trabectedin or Gemcitabine + Docetaxel in Metastatic or Locally Relapsed Uterine Leiomyosarcoma Pretreated With Conventional Chemotherapy Completed NCT02249702 Phase 2 gemcitabine + docetaxel;trabectedin
49 Phase II Trial of Gleevec (Formerly Known as STI571) in Patients With Soft Tissue and Bone Sarcomas: A Multi-Disciplinary Trial of the North American Sarcoma Study Group of the Connective Tissue Oncology Society Completed NCT00031915 Phase 2 imatinib mesylate
50 A Phase II Study of Intravenous TZT-1027, Administered Weekly Times Two, Every Three Weeks, to Patients With Advanced or Metastatic Soft Tissue Sarcomas (STS) With Prior Exposure to Anthracycline-Based Chemotherapy Completed NCT00064220 Phase 2 soblidotin

Search NIH Clinical Center for Liposarcoma

Cochrane evidence based reviews: liposarcoma

Genetic Tests for Liposarcoma

Anatomical Context for Liposarcoma

MalaCards organs/tissues related to Liposarcoma:

41
Bone, Breast, Adipocyte, Kidney, Lung, Skin, T Cells

Publications for Liposarcoma

Articles related to Liposarcoma:

(show top 50) (show all 5439)
# Title Authors PMID Year
1
The role of autophagy: what can be learned from the genetic forms of amyotrophic lateral sclerosis. 9 38
20406184 2010
2
Neuronal death in amyotrophic lateral sclerosis (ALS): what can we learn from genetics? 9 38
20406185 2010
3
Protein aggregation and defective RNA metabolism as mechanisms for motor neuron damage. 9 38
20406182 2010
4
Well-differentiated spindle cell liposarcoma ('atypical spindle cell lipomatous tumor') does not belong to the spectrum of atypical lipomatous tumor but has a close relationship to spindle cell lipoma: clinicopathologic, immunohistochemical, and molecular analysis of six cases. 9 38
20228779 2010
5
Specificity of fusion genes in adipocytic tumors. 9 38
20332486 2010
6
Significance of LRP and PPAR-gamma Expression in Lipomatous Soft Tissue Tumors. 9 38
20224740 2010
7
[Identification of genes over-expressed in myxoid/round cell liposarcoma. DNA microarray analysis and immunohistochemical correlation]. 9 38
19823827 2010
8
Well-differentiated and dedifferentiated liposarcomas. 9 38
19688222 2010
9
Carboxypeptidase M: a biomarker for the discrimination of well-differentiated liposarcoma from lipoma. 9 38
19820690 2009
10
Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours. 9 38
19946100 2009
11
Similarity in genetic alterations between paired well-differentiated and dedifferentiated components of dedifferentiated liposarcoma. 9 38
19734852 2009
12
Selective elimination of amplified CDK4 sequences correlates with spontaneous adipocytic differentiation in liposarcoma. 9 38
19626636 2009
13
Pseudosarcomatous fibroblastic/myofibroblastic proliferation in perinephric adipose tissue adjacent to renal cell carcinoma: a lesion mimicking well-differentiated liposarcoma. 9 38
19525929 2009
14
Rhabdomyomatous well-differentiated liposarcoma arising in giant fibrovascular polyp of the esophagus. 9 38
19608085 2009
15
Structural basis and specificity of human otubain 1-mediated deubiquitination. 9 38
18954305 2009
16
Primary retroperitoneal myxoid/round cell liposarcoma is a nonexisting disease: an immunohistochemical and molecular biological analysis. 9 38
18820664 2009
17
Detection of MDM2 gene amplification or protein expression distinguishes sclerosing mesenteritis and retroperitoneal fibrosis from inflammatory well-differentiated liposarcoma. 9 38
18836421 2009
18
Mixed-type liposarcoma: clinicopathological, immunohistochemical, and molecular analysis of a case arising in deep soft tissues of the lower extremity. 9 38
18551309 2008
19
SMARCB1/INI1 protein expression in round cell soft tissue sarcomas associated with chromosomal translocations involving EWS: a special reference to SMARCB1/INI1 negative variant extraskeletal myxoid chondrosarcoma. 9 38
18580682 2008
20
Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms. 9 38
18500263 2008
21
Induced ncRNAs allosterically modify RNA-binding proteins in cis to inhibit transcription. 9 38
18509338 2008
22
FUS-DDIT3 prevents the development of adipocytic precursors in liposarcoma by repressing PPARgamma and C/EBPalpha and activating eIF4E. 9 38
18596980 2008
23
Immunostaining for peroxisome proliferator gamma distinguishes dedifferentiated liposarcoma from other retroperitoneal sarcomas. 9 38
18204431 2008
24
[Retroperitoneal giant mixed sarcoma. Case report]. 9 38
18507961 2008
25
Prognostic factors and expression of MDM2 in patients with primary extremity liposarcoma. 9 38
18438568 2008
26
High level of telomerase RNA gene expression is associated with chromatin modification, the ALT phenotype and poor prognosis in liposarcoma. 9 38
18414473 2008
27
Clinical Use of PPARgamma Ligands in Cancer. 9 38
19125177 2008
28
Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. 9 38
17638873 2007
29
Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. 9 38
17359542 2007
30
Pathology and genetics of adipocytic tumors. 9 38
18000364 2007
31
Chromosome-12 copy number alterations and MDM2, CDK4 and TP53 expression in soft tissue liposarcoma. 9 38
17214366 2006
32
Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4. 9 38
17018606 2006
33
Reproducibility of MDM2 and CDK4 staining in soft tissue tumors. 9 38
16707369 2006
34
Calretinin expression in tumors of adipose tissue. 9 38
16613326 2006
35
A novel germline mutation of MSH2 in a hereditary nonpolyposis colorectal cancer patient with liposarcoma. 9 38
16405554 2006
36
Round cell liposarcoma of scrotum with indolent course in young adult. 9 38
16536120 2005
37
Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP beta-mediated interleukin 6 expression. 9 38
15688424 2005
38
Alterations of cancer-related genes in soft tissue sarcomas: hypermethylation of RASSF1A is frequently detected in leiomyosarcoma and associated with poor prognosis in sarcoma. 9 38
15551306 2005
39
Multiple functional domains of the oncoproteins Spi-1/PU.1 and TLS are involved in their opposite splicing effects in erythroleukemic cells. 9 38
15064749 2004
40
[From cytogenetics to cytogenomics of adipose tissue tumors: 2. Malignant adipose tissue tumors]. 9 38
15242313 2004
41
Adipocyte low density lipoprotein receptor-related protein gene expression and function is regulated by peroxisome proliferator-activated receptor gamma. 9 38
12551936 2003
42
Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma. 9 38
12640106 2003
43
Different mRNA expression profile during tumor progression in a well-differentiated liposarcoma--A microdissection approach. 9 38
12924448 2003
44
Current strategies for anticancer chemoprevention and chemoprotection. 9 38
12669776 2002
45
Biochemical correlates of thiazolidinedione-induced adipocyte differentiation by high-resolution magic angle spinning NMR spectroscopy. 9 38
12353276 2002
46
A novel type of EWS-CHOP fusion gene in two cases of myxoid liposarcoma. 9 38
12169678 2002
47
RNA splicing mediated by YB-1 is inhibited by TLS/CHOP in human myxoid liposarcoma cells. 9 38
12168660 2002
48
The low density lipoprotein receptor-related protein contributes to selective uptake of high density lipoprotein cholesteryl esters by SW872 liposarcoma cells and primary human adipocytes. 9 38
11604390 2001
49
PPAR-gamma ligands inhibit growth of human esophageal adenocarcinoma cells through induction of apoptosis, cell cycle arrest and reduction of ornithine decarboxylase activity. 9 38
11494023 2001
50
Prospects for prevention and treatment of cancer with selective PPARgamma modulators (SPARMs). 9 38
11530334 2001

Variations for Liposarcoma

Cosmic variations for Liposarcoma:

9 (show top 50) (show all 234)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6978413 ZFHX3 soft tissue,fat,liposarcoma,myxoid-round cell c.448C>A p.L150M 16:72959698-72959698 12
2 COSM3054546 XPO1 soft tissue,fat,liposarcoma,myxoid-round cell c.1288G>T p.V430L 2:61493011-61493011 12
3 COSM6987297 WT1 soft tissue,fat,liposarcoma,myxoid-round cell c.223G>A p.E75K 11:32434919-32434919 12
4 COSM6986268 TSC1 soft tissue,fat,liposarcoma,myxoid-round cell c.1079C>A p.T360N 9:132911064-132911064 12
5 COSM11333 TP53 soft tissue,fat,liposarcoma,myxoid-round cell c.499C>T p.Q167* 17:7675113-7675113 12
6 COSM10648 TP53 soft tissue,fat,liposarcoma,pleomorphic c.524G>A p.R175H 17:7675088-7675088 12
7 COSM10672 TP53 soft tissue,fat,liposarcoma,pleomorphic c.577C>T p.H193Y 17:7674954-7674954 12
8 COSM10647 TP53 soft tissue,fat,liposarcoma,pleomorphic c.404G>T p.C135F 17:7675208-7675208 12
9 COSM10656 TP53 soft tissue,fat,liposarcoma,pleomorphic c.742C>T p.R248W 17:7674221-7674221 12
10 COSM45794 TP53 soft tissue,fat,liposarcoma,pleomorphic c.421T>G p.C141G 17:7675191-7675191 12
11 COSM44112 TP53 soft tissue,fat,liposarcoma,myxoid-round cell c.640C>T p.H214Y 17:7674891-7674891 12
12 COSM43632 TP53 soft tissue,fat,liposarcoma,pleomorphic c.493C>T p.Q165* 17:7675119-7675119 12
13 COSM10731 TP53 soft tissue,fat,liposarcoma,pleomorphic c.707A>G p.Y236C 17:7674256-7674256 12
14 COSM6848516 TET2 soft tissue,fat,liposarcoma,myxoid-round cell c.3809C>T p.T1270I 4:105259624-105259624 12
15 COSM6921522 SDHA soft tissue,fat,liposarcoma,myxoid-round cell c.664T>G p.L222V 5:228227-228227 12
16 COSM1437480 RICTOR soft tissue,fat,liposarcoma,pleomorphic c.3404C>T p.T1135M 5:38950444-38950444 12
17 COSM1651764 RB1 soft tissue,fat,liposarcoma,pleomorphic c.1818T>A p.Y606* 13:48456207-48456207 12
18 COSM6966300 RB1 soft tissue,fat,liposarcoma,pleomorphic c.2632G>A p.D878N 13:48476812-48476812 12
19 COSM6906362 RAF1 soft tissue,fat,liposarcoma,pleomorphic c.1141G>A p.D381N 3:12591760-12591760 12
20 COSM5106 PTEN soft tissue,fat,liposarcoma,myxoid-round cell c.335T>C p.L112P 10:87933094-87933094 12
21 COSM5135 PTEN soft tissue,fat,liposarcoma,myxoid-round cell c.106G>A p.G36R 10:87894051-87894051 12
22 COSM5039 PTEN soft tissue,fat,liposarcoma,myxoid-round cell c.518G>A p.R173H 10:87952143-87952143 12
23 COSM1167954 PTEN soft tissue,fat,liposarcoma,myxoid-round cell c.485A>T p.D162V 10:87933244-87933244 12
24 COSM3416650 POLE soft tissue,fat,liposarcoma,myxoid-round cell c.2275C>T p.R759C 12:132667547-132667547 12
25 COSM6987724 PLK2 soft tissue,fat,liposarcoma,myxoid-round cell c.1337G>C p.R446P 5:58456073-58456073 12
26 COSM775 PIK3CA soft tissue,fat,liposarcoma,myxoid-round cell c.3140A>G p.H1047R 3:179234297-179234297 12
27 COSM760 PIK3CA soft tissue,fat,liposarcoma,myxoid-round cell c.1624G>A p.E542K 3:179218294-179218294 12
28 COSM754 PIK3CA soft tissue,fat,liposarcoma,myxoid-round cell c.1035T>A p.N345K 3:179203765-179203765 12
29 COSM12597 PIK3CA soft tissue,fat,liposarcoma,myxoid-round cell c.3145G>C p.G1049R 3:179234302-179234302 12
30 COSM763 PIK3CA soft tissue,fat,liposarcoma,myxoid-round cell c.1633G>A p.E545K 3:179218303-179218303 12
31 COSM6903888 NOTCH2 soft tissue,fat,liposarcoma,myxoid-round cell c.5857C>T p.R1953C 1:119918478-119918478 12
32 COSM24452 NF1 soft tissue,fat,liposarcoma,pleomorphic c.1105C>T p.Q369* 17:31201079-31201079 12
33 COSM28019 NF1 soft tissue,fat,liposarcoma,pleomorphic c.4006C>T p.Q1336* 17:31249015-31249015 12
34 COSM6987300 NCOR1 soft tissue,fat,liposarcoma,myxoid-round cell c.4256C>T p.P1419L 17:16070422-16070422 12
35 COSM175679 MUTYH soft tissue,fat,liposarcoma,myxoid-round cell c.536G>A p.R179H 1:45332794-45332794 12
36 COSM6978412 MUTYH soft tissue,fat,liposarcoma,myxoid-round cell c.1022C>T p.P341L 1:45331816-45331816 12
37 COSM6987286 MLH1 soft tissue,fat,liposarcoma,myxoid-round cell c.2146G>A p.V716M 3:37050528-37050528 12
38 COSM517 KRAS soft tissue,fat,liposarcoma,myxoid-round cell c.34G>A p.G12S 12:25245351-25245351 12
39 COSM6906365 KMT2C soft tissue,fat,liposarcoma,pleomorphic c.12200C>A p.P4067H 7:152154086-152154086 12
40 COSM6906367 KMT2A soft tissue,fat,liposarcoma,pleomorphic c.8086C>T p.R2696* 11:118503987-118503987 12
41 COSM6924116 KMT2A soft tissue,fat,liposarcoma,myxoid-round cell c.5783G>T p.G1928V 11:118498063-118498063 12
42 COSM1651756 KIT soft tissue,fat,liposarcoma,myxoid-round cell c.2334G>C p.K778N 4:54731971-54731971 12
43 COSM216207 KDM6A soft tissue,fat,liposarcoma,pleomorphic c.3768C>G p.Y1256* 23:45090754-45090754 12
44 COSM1645298 JAK1 soft tissue,fat,liposarcoma,pleomorphic c.1595G>A p.R532H 1:64855562-64855562 12
45 COSM6987289 GATA2 soft tissue,fat,liposarcoma,myxoid-round cell c.436G>A p.G146S 3:128486162-128486162 12
46 COSM6664414 FLCN soft tissue,fat,liposarcoma,pleomorphic c.247G>A p.E83K 17:17227891-17227891 12
47 COSM6934579 FAT1 soft tissue,fat,liposarcoma,pleomorphic c.2806G>A p.V936I 4:186707022-186707022 12
48 COSM6934578 FAT1 soft tissue,fat,liposarcoma,pleomorphic c.2806G>A p.V936I 4:186707022-186707022 12
49 COSM6906369 ERBB2 soft tissue,fat,liposarcoma,pleomorphic c.2441G>A p.R814H 17:39724859-39724859 12
50 COSM1056635 EPHA5 soft tissue,fat,liposarcoma,pleomorphic c.1702G>A p.D568N 4:65404462-65404462 12

Copy number variations for Liposarcoma from CNVD:

7 (show all 36)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13334 1 1 124300000 Gain Liposarcoma
2 16445 1 124300000 247249719 Loss Liposarcoma
3 20078 1 15300000 163800000 Amplification COAS1 Liposarcoma
4 20079 1 15300000 163800000 Amplification COAS2 Liposarcoma
5 20080 1 15300000 163800000 Amplification COAS3 Liposarcoma
6 20084 1 15300000 212100000 Gain Liposarcoma
7 42815 10 40300000 135374737 Loss Liposarcoma
8 55437 11 52900000 134452384 Loss Liposarcoma
9 61489 12 1 14800000 Loss Liposarcoma
10 67172 12 37282278 37312244 Amplified CHOP Liposarcoma
11 67787 12 44600000 69800000 Gain CDK4 liposarcomas
12 67788 12 44600000 69800000 Gain HMGA2 liposarcomas
13 67789 12 44600000 69800000 Gain MDM2 liposarcomas
14 69651 12 56140200 56152312 Amplified GLI1 Liposarcoma
15 69861 12 56374152 56401607 Amplified OS9 Liposarcoma
16 69873 12 56425050 56428293 Amplified TSPAN31 Liposarcoma
17 69880 12 56428269 56432431 Amplified CDK4 Liposarcoma
18 70737 12 64503703 64646338 Amplified HMGA2 Liposarcoma
19 71088 12 67488246 67520481 Amplified MDM2 Liposarcoma
20 77049 13 39500000 52200000 Loss Liposarcoma
21 77649 13 46200000 52200000 Deletion RB1 Liposarcoma
22 78496 13 52200000 114142980 Loss Liposarcoma
23 106733 17 1 11200000 Deletion Liposarcoma
24 108852 17 23200000 28800000 Deletion Liposarcoma
25 139560 2 183406981 183439743 Amplified OS1 Liposarcoma
26 149783 2 93300000 242951149 Gain Liposarcoma
27 149786 2 93300000 242951149 Loss Liposarcoma
28 166153 3 1 91700000 Gain Liposarcoma
29 166161 3 1 91700000 Loss Liposarcoma
30 179460 3 91700000 199501827 Gain Liposarcoma
31 187537 4 50700000 191273063 Loss Liposarcoma
32 191663 5 1 45800000 Gain Liposarcoma
33 200009 5 47700000 180857866 Gain Liposarcoma
34 210239 6 29900000 45200000 Gain Liposarcoma
35 217105 7 1 59100000 Gain Liposarcoma
36 225569 7 47600000 107200000 Gain Liposarcoma

Expression for Liposarcoma

Search GEO for disease gene expression data for Liposarcoma.

Pathways for Liposarcoma

Pathways related to Liposarcoma according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.75 TP53 PPARG MDM2 CDKN2A CDK4
2 12.72 TP53 PPARG MDM2 CDKN2A CDK4
3 12.32 VIM TP53 MDM2 HMGA2 CDKN2A
4 12.27 VIM TP53 MDM2 CDKN2A CDK4
5
Show member pathways
12.25 TP53 MDM2 CDKN2A CDK4
6 12.24 TP53 MDM2 CDKN2A CDK4
7 12.23 TP53 GPS2 CDKN2A CDK4
9 12.14 TP53 MDM2 CDKN2A CDK4
10 12.11 YBX1 FUS EWSR1 DDIT3
11 12 TP53 MDM2 CDKN2A CDK4
12 11.73 TP53 MDM2 CDK4
13 11.71 TP53 MDM2 CDKN2A CDK4
14
Show member pathways
11.61 TP53 MDM2 CDKN2A
15 11.6 TP53 MDM2 CDKN2A
16 11.44 TP53 PPARG MDM2 HMGA2 FUS EWSR1
17 11.42 TP53 MDM2 CDKN2A
18 11.32 TP53 MDM2 CDK4
19 11.32 TP53 MDM2 CDKN2A CDK4
20 11.28 TP53 MDM2 CDK4
21
Show member pathways
10.84 TP53 MDM2 CDKN2A
22 10.78 TP53 MDM2 CDKN2A
23 10.76 TP53 MDM2 CDKN2A CDK4

GO Terms for Liposarcoma

Cellular components related to Liposarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.86 YBX1 VIM TSN TP53 PPARG MDM2
2 nucleus GO:0005634 9.55 YBX1 VIM TSN TP53 PPARG PPARA
3 senescence-associated heterochromatin focus GO:0035985 9.16 HMGA2 CDKN2A
4 cytosol GO:0005829 10.13 YBX1 VIM TSN TP53 PPARG MDM2
5 nucleoplasm GO:0005654 10 YBX1 TP53 PPARG PPARA MDM2 HMGA2

Biological processes related to Liposarcoma according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.91 TP53 PPARG PPARA HMGA2 DDIT3 CDKN2A
2 heart development GO:0007507 9.86 PPARG PPARA MDM2 MB
3 positive regulation of apoptotic process GO:0043065 9.85 TP53 PPARG HMGA2 CDKN2A CDK4
4 negative regulation of transcription by RNA polymerase II GO:0000122 9.8 TP53 PPARG PPARA MDM2 HMGA2 GPS2
5 regulation of lipid metabolic process GO:0019216 9.78 PPARG PPARA GPS2
6 positive regulation of transcription by RNA polymerase II GO:0045944 9.76 YBX1 TP53 PPARG PPARA HMGA2 GPS2
7 negative regulation of neuron projection development GO:0010977 9.7 VIM MDM2 LRP1
8 positive regulation of cholesterol efflux GO:0010875 9.61 LRP1 GPS2
9 replicative senescence GO:0090399 9.6 TP53 CDKN2A
10 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.59 PPARG PPARA
11 positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress GO:1990440 9.58 TP53 DDIT3
12 negative regulation of telomerase activity GO:0051974 9.58 TP53 PPARG
13 ER overload response GO:0006983 9.57 TP53 DDIT3
14 amyloid fibril formation GO:1990000 9.55 MDM2 CDKN2A
15 negative regulation of cholesterol storage GO:0010887 9.54 PPARG PPARA
16 positive regulation of fatty acid oxidation GO:0046321 9.49 PPARG PPARA
17 negative regulation of sequestering of triglyceride GO:0010891 9.48 PPARG PPARA
18 positive regulation of gene expression GO:0010628 9.43 VIM TP53 MDM2 HMGA2 CDKN2A CD34
19 senescence-associated heterochromatin focus assembly GO:0035986 9.4 HMGA2 CDKN2A
20 negative regulation of receptor biosynthetic process GO:0010871 9.37 PPARG PPARA
21 cellular response to actinomycin D GO:0072717 9.32 TP53 MDM2
22 negative regulation of transcription, DNA-templated GO:0045892 9.17 TP53 PPARG PPARA MDM2 HMGA2 DDIT3
23 regulation of transcription, DNA-templated GO:0006355 10.11 YBX1 TP53 PPARG PPARA HMGA2 FUS

Molecular functions related to Liposarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.91 YBX1 TSN TP53 PPARG PPARA HMGA2
2 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.72 YBX1 TP53 PPARA HMGA2 DDIT3
3 transcription regulatory region DNA binding GO:0044212 9.71 TP53 PPARG HMGA2 DDIT3
4 identical protein binding GO:0042802 9.56 VIM TSN TP53 PPARG MDM2 FUS
5 transcription regulatory region sequence-specific DNA binding GO:0000976 9.54 PPARG PPARA DDIT3
6 disordered domain specific binding GO:0097718 9.33 TP53 MDM2 CDKN2A
7 transcription factor binding GO:0008134 9.17 TP53 PPARG PPARA HMGA2 DDIT3 CDKN2A

Sources for Liposarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....